UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2020
(Exact name of registrant as specified in its charter)
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (301 ) 251-5172
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered Pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On February 27, 2020, Jon Wigginton, M.D., Senior Vice President, Clinical Development and Chief Medical Officer of MacroGenics, Inc. (the “Company”), notified the
Company of his resignation, effective March 27, 2020. Dr. Wigginton will be leaving the Company to pursue a new opportunity.
While the executive search for a new Chief Medical Officer is ongoing, Ezio Bonvini, M.D., Senior Vice President, Research and Chief Scientific Officer, will assume Dr. Wigginton’s responsibilities on an interim basis, including leading clinical development and related functions. Dr. Bonvini joined the Company in
June 2003. He was previously with the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER) for 18 years, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies. Dr. Bonvini
received his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.
| Item 7.01 |
Regulation FD Disclosure.
|
On March 4, 2020, the Company issued a press release (the “Press Release”) announcing the resignation of Dr. Wigginton and the appointment of Dr. Bonvini as head of
Clinical Development on an interim basis. A copy of the Press Release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
|
Press Release, dated March 4, 2020.
|
||
|
104
|
Cover Page Interactive Data (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MACROGENICS, INC.
|
||
|
Dated: March 4, 2020
|
By:
|
/s/ Jeffrey Peters
|
|
Name:
|
Jeffrey Peters
|
|
|
Title:
|
Vice President and General Counsel
|
|
Exhibit 99.1
MacroGenics Announces Departure of Chief Medical Officer
ROCKVILLE, MD, March 4, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development & Chief
Medical Officer, will be leaving the Company effective March 27, 2020 to pursue a new opportunity.
“Over the past seven years, Jon has played a leadership role in establishing and executing the clinical development strategy to advance our immuno-oncology product
candidates. I would like to thank him for his significant contributions to MacroGenics, and wish him the best in his future endeavors,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Our clinical programs are progressing as
planned, and we look forward to a productive 2020.”
While the executive search for a new Chief Medical Officer is ongoing, Ezio Bonvini, M.D., Senior Vice President, Research and Chief Scientific Officer, will assume Dr. Wigginton’s responsibilities on an interim basis, including overseeing
clinical development and related functions. Dr. Bonvini joined MacroGenics in June 2003. He was previously with the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER) for 18 years, ultimately serving as
Acting Deputy Director, Division of Monoclonal Antibodies. Dr. Bonvini received his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of
cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see
the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations,
clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements
containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of
strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing
clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners and other
matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of
any date subsequent to the date hereof.
Contacts:
Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com